Sunny Outlook for Personalized Medicine: Tamoxifen and Beyond

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

WA Teft is a recipient of the Canadian Institutes of Health Research (CIHR) Canada Drug Safety and Effectiveness Cross-Disciplinary Training (DSECT) Post-Doctoral Scholarship. RB Kim is supported by the Wolfe Medical Research Chair in Pharmacogenomics and grants from the CIHR Drug Safety and Effectiveness Network (DSEN) the Cancer Care Ontario (CCO) Research Chair Award (Tier-1) in Experimental Therapeutics and the Ontario Institute for Cancer Research (OICR) Translational Research Team grant. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

WA Teft is a recipient of the Canadian Institutes of Health Research (CIHR) Canada Drug Safety and Effectiveness Cross-Disciplinary Training (DSECT) Post-Doctoral Scholarship. RB Kim is supported by the Wolfe Medical Research Chair in Pharmacogenomics and grants from the CIHR Drug Safety and Effectiveness Network (DSEN) the Cancer Care Ontario (CCO) Research Chair Award (Tier-1) in Experimental Therapeutics and the Ontario Institute for Cancer Research (OICR) Translational Research Team grant. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.